Michael Hofman and colleagues report more frequent prostate-specific antigen response and prolonged progression-free survival with lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617, compared with cabazitaxel, in patients with metastatic castrationresistant prostate cancer with high prostate-specific membrane antigen (PSMA) expression.
Targeted radioactive therapy for prostate cancer
De Giorgi U.
Primo
;Paganelli G.Ultimo
2021
Abstract
Michael Hofman and colleagues report more frequent prostate-specific antigen response and prolonged progression-free survival with lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617, compared with cabazitaxel, in patients with metastatic castrationresistant prostate cancer with high prostate-specific membrane antigen (PSMA) expression.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
S0140673621013362.pdf
accesso aperto
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
131.06 kB
Formato
Adobe PDF
|
131.06 kB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
